11/18/2019 4:08:55 PM
Ovid Therapeutics Appoints Jason Tardio As Chief Commercial Officer
10/4/2019 8:34:40 AM
Ovid Therapeutics Prices $32.5 Mln Of Securities In Concurrent Public Offerings Of Common Stock And Preferred Stock
9/23/2019 7:07:58 AM
Ovid Therapeutics Announces Positive Initial Data From Ongoing ENDYMION Open-Label Extension Trial Of Soticlestat
7/2/2019 8:15:37 AM
Ovid Therapeutics Gets Orphan Drug Designation From European Commission For OV101 For Angelman Syndrome
1/4/2019 8:06:25 AM
Ovid Therapeutics : Pivotal Phase 3 NEPTUNE Trial Expected To Begin In H2 2019
12/17/2018 6:03:46 AM
Ovid Therapeutics Unveils Phase 1b/2a Results Of OV935/TAK-935 In Adults With Rare Epilepsies, Meets Primary End Point
11/20/2018 7:12:41 AM
Ovid Therapeutics Announces OV935/TAK-935 Presentations At American Epilepsy Society Annual Meeting
11/8/2018 7:41:40 AM
Ovid Therapeutics Q3 Net Loss $13.0 Mln Or $0.53/Shr Vs Loss Of $9.4 Mln Or $0.38/shr Last Year
10/25/2018 9:20:25 AM
Ovid Presents Addl Data And Analyses From The Phase 2 STARS Trial With OV101 For Treatment Of Angelman Syndrome
8/6/2018 7:06:15 AM
Ovid Therapeutics Says OV101 Achieved Primary Endpoint Of Safety And Tolerability
7/18/2018 7:42:54 AM
Takeda And Ovid Therapeutics Expand Clinical Program For TAK-935/OV935
7/11/2018 7:31:07 AM
Ovid Therapeutics Begins Phase 2 ROCKET Clinical Trial To Evaluate OV101 In Fragile X Syndrome